Milan - Delayed Quote EUR

Pharmanutra S.p.A. (PHN.MI)

Compare
57.40 +1.00 (+1.77%)
As of 3:46 PM GMT+1. Market Open.
Loading Chart for PHN.MI
DELL
  • Previous Close 56.40
  • Open 55.50
  • Bid 57.30 x --
  • Ask 57.40 x --
  • Day's Range 55.50 - 57.40
  • 52 Week Range 44.85 - 63.50
  • Volume 594
  • Avg. Volume 4,957
  • Market Cap (intraday) 569.096M
  • Beta (5Y Monthly) 0.31
  • PE Ratio (TTM) 38.01
  • EPS (TTM) 1.51
  • Earnings Date --
  • Forward Dividend & Yield 0.85 (1.51%)
  • Ex-Dividend Date May 6, 2024
  • 1y Target Est 80.30

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company's products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. It distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. The company was founded in 2003 and is based in Pisa, Italy.

www.pharmanutra.it

112

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PHN.MI

View More

Performance Overview: PHN.MI

Trailing total returns as of 10/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PHN.MI
3.46%
FTSE MIB Index
15.13%

1-Year Return

PHN.MI
20.69%
FTSE MIB Index
28.06%

3-Year Return

PHN.MI
11.88%
FTSE MIB Index
30.36%

5-Year Return

PHN.MI
207.87%
FTSE MIB Index
54.56%

Compare To: PHN.MI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHN.MI

View More

Valuation Measures

Annual
As of 10/25/2024
  • Market Cap

    541.89M

  • Enterprise Value

    547.13M

  • Trailing P/E

    37.35

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.02

  • Price/Book (mrq)

    9.89

  • Enterprise Value/Revenue

    5.05

  • Enterprise Value/EBITDA

    19.15

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.47%

  • Return on Assets (ttm)

    14.04%

  • Return on Equity (ttm)

    28.01%

  • Revenue (ttm)

    107.61M

  • Net Income Avi to Common (ttm)

    14.5M

  • Diluted EPS (ttm)

    1.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.81M

  • Total Debt/Equity (mrq)

    49.36%

  • Levered Free Cash Flow (ttm)

    14.48M

Research Analysis: PHN.MI

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 32.68M
Earnings 6.27M
 

Analyst Price Targets

76.00
80.30 Average
57.40 Current
86.00 High
 

Company Insights: PHN.MI

People Also Watch